Member Info for AquaeSulis01

"ADM Releases Top Predictions for Global Microbiome Market
06/29/2022
Global nutrition leader outlines the emerging trends shaping the fast-growing microbiome segment in the year ahead

CHICAGO--(BUSINESS WIRE)-- ADM (NYSE:ADM), a global leader in nutrition that powers many of the world’s top food, beverage, health and wellness brands, today released its outlook on the global human microbiome market, which is expected to balloon to nearly $9.1 billion by 2026. 1

The findings, based on research from ADM’s proprietary Outside VoiceSM consumer insights platform, highlight the consumer trends shaping the fast-growing market for solutions that include prebiotics, probiotics, and increasingly, postbiotics. This deep dive into the microbiome segment builds on the release of ADM’s 2022 Global Consumer Trends report, which showcased the eight areas of focus for food, beverage, health and wellness, and animal nutrition brands this year.
The top five trends shaping the sector this year include:

Growing consumer awareness of the gut-brain connection and the link between microbiome function with mood and cognition
In partnership with FMCG Gurus, ADM’s Outside VoiceSM research found that more than half (58%) of global consumers are aware of the potential benefits that bacteria of the digestive tract may have on aspects of health and well-being3.
Personalized nutrition solutions designed to support everyday performance for Olympians and Weekend Warriors alike
Consumers are adopting a more holistic view of their diet and lifestyle choices, with gut health at the center. The microbiome has become the new frontier for the next generation of personalized nutrition, with growing evidence of links to sleep hygiene, overall mental well-being, immune function and more. Protein bars and ready-to-drink shakes are household staples for all active lifestyles—soon they will be tailored to support each individual's specific activity and lifestyle needs.
Consumers are using test-kits to benchmark the make-up of their microbiome as the personalized nutrition phenomenon gains hold
Demystification of probiotics and the skin microbiome
Consumer interest in immune health will be a top priority today and in the future
https://investors.adm.com/news/news-details/2022/ADM-Releases-Top-Predictions-for-Global-Microbiome-Market/default.aspx

The company has significantly derisked on what looks to be a successful SOEC demonstrator build to date, tech stocks in US again took a hit yesterday because of perceived poor consumer confidence, treat this as an investment rather than a trade now and wait for the sentiment to change and the profits to roll in

looking at your posting history across a number of companies looks like your having a pretty torrid time which may help to explain your unjustified angry post here; perhaps you ought to change your name to rogered

Guess you can't go too far wrong buying opti at the current M/C of £0 with zero debt and the skin and Probiotix Health investments making up the total of the current M/C. Also the £3M Cenkos forecast for next year does not include any revenue from THG, and Nahdi Medical and Apollo Hospitals assuming they launch H2

Answers my earlier question, shell have quickly snapped up the Ceres SOEC Demonstrator in development
"A 1MW solid-oxide demonstrator will be delivered to Shell in 2023 through the partnership.

“Given that Ceres will only launch the demonstrator in the second half of this year underlines the current appetite from energy majors to consider solid oxide within the technology mix for hydrogen production”, said Berenberg."
Berenberg points out that the potential for Ceres in the electrolyser market is hardly reflected in its market value.

The broker believes the electrolysis opportunity could be worth £150mln-200mln pa in high-margin royalty revenues to Ceres by 2035, while it can leverage 20 years of fuel cell stack development including the same IP portfolio, the same supply chain and the same manufacturing processes.

Shell also adds to Ceres’s already impressive list of blue-chip collaborations (eg Bosch, and Weichai) and, crucially, also suggests overall growth in interest for solid oxide electrolysis technology.

"Thus far, the industry has been dominated by alkaline and, more recently, proton exchange membrane technology – indeed Shell is collaborating with Thyssenkrupp and ITM Power to this extent.

“But there is increasing evidence that solid oxide is now also being considered to help deliver net-zero targets with Ceres’s peers Haldor Topsoe and Sunfire also making steady progress.

“It is worth noting that both Doosan and Bosch (Ceres’s fuel cell partners) have announced intentions to develop electrolyser businesses.”

Berenberg has a target of 1,560p against a market price of 589p, up 2.8% today."

https://www.proactiveinvestors.co.uk/companies/news/986062/ceres-power-s-partnership-with-shell-a-milestone-says-berenberg-986062.html

Certainly seen as an "order" from Shell in some quarters
"Shell orders electrolyser demo from Ceres"
https://renewablesnow.com/news/shell-orders-electrolyser-demo-from-ceres-789697/

Just to clarify, is this demonstrator in addition to or instead of the demonstrator referred to in the EOY RNS? "First-of-a-kind solid oxide electrolyser (SOEC) 1MW-scale demonstrator in build to become operational in 2022"

As you would expect, no real difference from the unaudited report, currently reliant on the sale of skin shares to maintain a positive cash balance and the "profit" gain in the skin investment will turn to a loss when the interims to 30th June 2022 are produced because of the dramatic fall in its share price.
No further update on sweetbiotix since the Feb Commercial RNS, so the optimisation to reduce production costs and waste is still ongoing and there has been slippage with the in-house launch of GoFigure products with Apollo Hospitals which in Feb we were told "is expected to take place in H1 and will progressively expand to other stores as well as online. Nahdi Medical plan to launch seven products Gofigure® / SlimBiome® Medical products in H1. OptiBiotix products are now increasingly becoming associated with internationally recognised retail, pharmaceutical partners and established brands."

Private equity consider ITV cheap. https://thetimes.pressreader.com/article/282574496761682

Via Probiotix Health v Sacco; LPLDL

Oleric, there is a clear link between psoriasis and certain forms of arthritis and if you listen to the bright study testimonials, more than one of the participants confirmed improved mobility through easing of their arthritis so it is not some random claim by elrico.
https://www.webmd.com/arthritis/psoriatic-arthritis/link-between-psoriasis-and-psoriatic-arthritis

What are you on about? Sweetbiotix is a second generation p rebiotic product not a compsny

Around 36 minutes in to the Sep Investor Meets presentation SO H states when talking about Material Transfer Agreements for sweetbiotix that he "was quite confident.he would get a number of deals landed in H2 2021', have a listen elrico

Thanks for the response elrico. Regarding the sweetbiotix forecast it came from SOH himself when he was speaking about Material Transfer Agreements during the Sep 21 Investor Meets presentation. The Q&A s documented for the subsequent Dec 21 Investor Meets also indicated we could expect a sweetbiotix announcement either side of Christmas

A long delay to a sweetbiotix deal would be disappointing bearing in mind taste tests have already been carried out. On the modulator front "Microbiome Modulators (MM's): The Company has developed an innovative approach to allow it to precision engineer the microbiome. This is one of the most exciting areas of microbiome therapeutics as it creates the potential for targeted treatment of a range of human diseases. The Company has demonstrated it can selectively enhance a probiotic and enhance its health benefit demonstrating proof of concept for using MM's as a microbiome therapeutic. Development work was impacted by COVID reducing access to Universities and CRO's in 2020 and early 2021. This work has now progressed and we are pleased to report the Company has produced microbiome modulators using a process suitable for industrial scale up. Work is ongoing to optimise the process and test whether the functionality has been retained before initiating full scale up and commercialisation. This is a really exciting area of development which if successful, the Company believes could revolutionise the use of the microbiome therapies in healthcare. The Company will be increasing its investment in Microbiome Modulators to accelerate the development activities taking place." What do you think this could mean in terms commercial deals? And hope you are right with the skinbiotherapeutics f unding front

Leanbiome not pensions

elrico, opti has the option as you say to sell skin shares of it needs to which provides a measure of security in an environment where raising money is becoming a difficult and expensive business. In terms of sweetbiotix, we were told on Feb that final scale up has been achieved and the process is now being optimised which suggests may o occur before skinbiotix is ready at the end of the year as scale up only started in Late 2021. Also don't forget exciting news is awaited 're microphone modulators and pensions has added another revenue stream, so yes opti is cheap. On the skin front the market is no doubt saying that revenues may not start arriving in sufficient volumes to avoid the need for a fund raise as there is no piggy bank to draw on. Let's hope we are all pleasantly surprised in both companies

Got to be a candidate for the dumbest post of the day. Firstly, the dream here is to hit a district scale find that transforms the company finances and renders any charts meaningless. Secondly, we are in a bear market so Thatcher applies to just about every small cap stock out there

Echo toyin very good interview elri c with all pertinent questions addressed. Thanks to Stuart too for his frank responses

On a lighter note just been sent a 50% off code for opti cholbiome bp. Would think they would do a booming trade in those with everyone's portfolio cratering.